MedTrace Logo

The Effect of Androgen Receptor Polymorphism on Endometrial Cancer

NCT05157373 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-12-15

No results posted yet for this study

Summary

Endometrial tissue is a hormonal-dependent tissue in both pre- and postmenopausal period. The endometrial cells are expressing receptors for all sex hormones, mainly for estrogen, progesterone and androgens. The proper response of the endometrial cells on hormones is crucial for a well-balanced fluctuation of endometrial tissue. If, for any reason, these responses are altered, this may lead to benign or malignant lesions.

The androgens, through their receptors, decrease the proliferation of the endometrial cells. After menopause, the number of androgens receptors (ARs) increases in proportion to estrogen receptors and this may lead to endometrial atrophy. If the functionality of ARs is decreased, the effect of estrogen increases and this may possibly lead to endometrial hyperplasia or to endometrial cancer. The AR gene is located on the X chromosome and consists of 8 exons. Genetic research has shown that on exon 1, there is an area of trinucleotide Cytosine- Adenosine- Guanin (CAG) repeats which controls the functionality of the receptor. The more CAG repeats, the less responsive the receptor.

The goal of this research is to study the AR gene polymorphism and particularly the number of CAG repeats on exon 1, in patients with known endometrial pathology (benign and malignant). The results will be compared with a random sample of the general population without endometrial pathology.

Conditions

  • Androgen Receptor Abnormal
  • Endometrial Disorder

Interventions

DIAGNOSTIC_TEST

Endometrial sampling and Peripheral blood collection

The endometrial biopsy will be performed with a pipette. The pipelle will be inserted gently through the cervix and into the uterus. The pipelle procedure takes approximately one minute and involves gently moving the pipelle back and forth to obtain a sample. Then 10cc of peripheral blood will be collected.

BEHAVIORAL

FSFI Scale

The participants will fill up the Female Sexual Function Index (FSFI) questionnaire. The FSFI is a 19-item self-report questionnaire designed to measure sexual functioning in women. It assesses six domains of sexual function: sexual desire, sexual arousal, lubrication, orgasm, satisfaction, and pain (i.e., pain associated with vaginal penetration).

Sponsors & Collaborators

  • University of Nicosia

    lead OTHER

Principal Investigators

  • Maria Chryssi, MSh · Anticancer oncological hospital of Athens "St Savvas'

  • Dionysios Vaidakis, MD,PhD. · Department of Life & Health Sciences, University of Nicosia

  • Adonis Ioannides, MD,PhD. · Department of Life & Health Sciences, University of Nicosia

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-04-01
Completion
2024-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05157373 on ClinicalTrials.gov